SimonMed, one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States, announced its implementation of SyntheticMR’s SyMRI software to support enhanced lesion detection and allow for quantitative MRI including the tracking of myelin development in pediatric patients and patients with Multiple Sclerosis.
“The quantification of myelin through SyntheticMR is an example of our rapid progress beyond 3T MRI to use the latest MR technology to further improve diagnoses,” said Dr. John Simon, MD, Chief Executive of SimonMed. “I expect the partnership with SyntheticMR will yield many new technologies that will quickly improve patient care.”
“SyntheticMR is excited to partner with SimonMed.” says Kyle Frye, President, SyntheticMR Inc. “Dr. Simon and his team understand the value of continuously offering patients and their referring providers best in class technology that has the patients experience at the forefront of what they do. SimonMed will be utilizing our tissue segmentation and myelin quantification across multiple sites and states, allowing for a truly integrated solution.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
About SyntheticMR AB
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB’s product SyMRI® delivers multiple contrast images and quantitative data from a single 6-minute scan. The product is available in different packages. SyMRI IMAGE supports faster MRI workflows and improved patient throughput. SyMRI NEURO delivers automatic segmentation of brain tissue, supporting objective decision support. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the Spotlight Stock Market in Stockholm, Sweden.